menu
Your Cart

ITA7438

ITA7438-1
ITA7438-2
ITA7438-1
ITA7438-2
ITA7438
  • Catalog: ITA7438
  • Gene/Protein: IL27
  • Product Description: Immunotag™ IL27 Antibody
385.0000
Price in reward points: 385

Available Options

Immunotag™ IL27 Antibody
Antibody Specification
Datasheet

Target Protein IL27
Clonality Polyclonal
Storage/Stability -20°C/1 year
Application WB,IHC,ELISA
Recommended Dilution WB 1:500-1:2000 IHC 1:50-1:200
Concentration 1 mg/ml
Reactive Species Human,Mouse,Rat
Host Species Rabbit
Immunogen A synthesized peptide derived from human IL27
Specificity IL27 Antibody detects endogenous levels of total IL27
Purification The antiserum was purified by peptide affinity chromatography.
Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt
Gene Name IL27
Accession No. Q8NEV9
Alternate Names EBI3; IL 27; IL 27 p28 subunit; IL 27A; IL 30; IL-27 subunit alpha; IL-27-A; IL27; IL27-A; IL27A; IL27A_HUMAN; IL27p28; IL30; Interleukin 27; Interleukin 27 subunit alpha; Interleukin 27, 28-KD subunit; Interleukin 30; Interleukin-27 subunit alpha; p28;
Description Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication.
Cell Pathway/ Category Primary Polyclonal Antibody
Protein MW 27kDa
Usage For Research Use Only! Not for diagnostic or therapeutic procedures.
Material Safety Data Sheet
English_US
Danish
Dutch
English_UK
French
German
Spanish
Norwegian
Portuguese
Finnish
Swedish
Polish

Write a review

Note: HTML is not translated!
Bad Good
Captcha

CONNECT WITH US